Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC

INTRODUCTION: Alectinib is a preferred first-line treatment option for advanced ALK-positive NSCLC. Combination regimens of alectinib with immune checkpoint inhibitors are being evaluated for synergistic effects. METHODS: Adults with treatment-naive, stage IIIB/IV, or recurrent ALK-positive NSCLC we...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dong-Wan, Gadgeel, Shirish, Gettinger, Scott N., Riely, Gregory J., Oxnard, Geoffrey R., Mekhail, Tarek, Schmid, Peter, Dowlati, Afshin, Heist, Rebecca S., Wozniak, Antoinette J., Singh, Jatinder, Cha, Edward, Spahn, Jessica, Ou, Sai-Hong Ignatius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304608/
https://www.ncbi.nlm.nih.gov/pubmed/35875467
http://dx.doi.org/10.1016/j.jtocrr.2022.100367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304608/
https://www.ncbi.nlm.nih.gov/pubmed/35875467
http://dx.doi.org/10.1016/j.jtocrr.2022.100367

Ejemplares similares